Navigation Links
Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
Date:5/15/2009

SEATTLE, May 15 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that data from CTI's pivotal phase III EXTEND (PIX301) trial of pixantrone in patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL) will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 29 to June 2, 2009 in Orlando, Florida.

Ruth Pettengell, M.D. of St. George's Hospital, University of London, an investigator on the study, is scheduled to present the data on Monday, June 1, 2009 during the Lymphoma and Plasma Cell Disorders session that will be held from 2:00 PM-6:00 PM Eastern Time. The presentation, abstract #8523, is titled, "Randomized Phase III trial of pixantrone compared with other chemotherapeutic agents for third-line single-agent treatment of relapsed aggressive non-Hodgkin's lymphoma." The abstract is available at www.asco.org.

CTI expects to complete the submission of a New Drug Application ("NDA") for pixantrone this quarter and will request priority review which if granted could lead to an approval decision from the U.S. Food and Drug Administration ("FDA") during the fourth quarter of 2009.

About Pixantrone

Pixantrone (BBR 2778), is a novel major groove binder with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to r
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
2. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
3. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
4. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
5. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
6. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
7. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
8. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
9. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
10. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015 ... for Enterprise, having more than doubled its overseas sales ... PharmaGenesis today celebrates winning the Queen,s Award for Enterprise, ... is the world,s first HealthScience Communications consultancy, helping its ... of patient need. Having more than doubled its exports ...
(Date:4/21/2015)... Cardiologists at Henry Ford Hospital have implanted a device that ... heartbeat. With only handful of hospitals in the ... to add another option to its arsenal of tools for ... to pump. "This is a first in ... at a non-clinical trial site," says cardiologist Claudio Schuger ...
(Date:4/21/2015)... , April 21, 2015  St. Vincent ... to patient care. Already following strict disinfection routines, ... Tru-D SmartUVC to eliminate harmful germs, like Ebola, ... and norovirus that can infect patients during their ... Logo - http://photos.prnewswire.com/prnh/20150420/199749LOGO ...
Breaking Medicine Technology:Queen's Award Crowns Achievements of Local Consultancy 2Queen's Award Crowns Achievements of Local Consultancy 3Queen's Award Crowns Achievements of Local Consultancy 4Queen's Award Crowns Achievements of Local Consultancy 5Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 2Stroke Risk Caused by Abnormal Heart Rhythm Reduced Without Blood Thinners 3St. Vincent Healthcare Deploys Germ-Killing Robot to Prevent Infection, Protect Patients During Hospital Visits 2St. Vincent Healthcare Deploys Germ-Killing Robot to Prevent Infection, Protect Patients During Hospital Visits 3
... NEW YORK, April 14, 2011 Dr. David Samadi, Vice ... at The Mount Sinai Medical Center in New York City , ... month in the British Medical Journal ( ... 1,500 of whom were screened for prostate cancer every ...
... Calif., April 14, 2011 Freedom Innovations, a ... technology lower extremity prosthetic devices, today announced a ... exclusive rights to commercialize the world,s first lower ... joints that operate synergistically.  Developed at the Vanderbilt ...
Cached Medicine Technology:Does Prostate Cancer Screening Reduce Mortality Rates? 2Does Prostate Cancer Screening Reduce Mortality Rates? 3Does Prostate Cancer Screening Reduce Mortality Rates? 4Freedom Innovations to Commercialize the World's First Actively-Powered, Complete Lower Extremity Prosthesis 2Freedom Innovations to Commercialize the World's First Actively-Powered, Complete Lower Extremity Prosthesis 3
(Date:4/21/2015)... 2015 AvePoint, the established ... today announced a new enhancement to DocAve Policy ... Office 365 Management Activity API. This integration creates a ... and take action on all events that take place ... 365 Management Activity API provides customers with greater transparency ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Wireless ... services, has been recognized by the Boston Business Journal ... The ranking was announced at a recent event celebrating ... list of the fastest-growing private companies in Massachusetts. , ... in the state that recorded the fastest revenue growth ...
(Date:4/21/2015)... April 21, 2015 Lowcostcarinsuranceprice.com has released a ... auto insurance for SUVs. , SUVs are large ... collision between an SUV and a smaller regular car shows ... of surviving. This makes SUV safer in crashes, but these ... in certain situation. , It is now possible to ...
(Date:4/21/2015)... The report “Dermatitis – ... on the therapeutic development for Dermatitis. ... new targets and MOAs to produce first-in-class ... is available @ http://www.rnrmarketresearch.com/dermatitis-pipeline-review-h1-2015-market-report.html . ... involved in the therapeutic development for Dermatitis ...
(Date:4/21/2015)... has released a new blog post presenting heavily circulated ... insurance prices . , Commuting on heavy circulated ... their insurance options before deciding what plan to buy. ... of the popular policies provide liability, collision or comprehensive ... find the best prices in their area simply by ...
Breaking Medicine News(10 mins):Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 2Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 3Health News:Wireless Analytics Ranked as 25th Fastest Growing Private Company in Massachusetts 2Health News:Auto Insurance Quotes For SUVs Are Available Online 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:Heavily Circulated Roads Can increase Auto Insurance Costs 2
... hair loss in people as young as 16 whereas the phenomenon ... ,"Nobody can escape stress in modern day life. Stress ... the thinning of hair," Mumbai-based Sonal Shah said. ,"Initially, ... has come down to as low as 16 and 18," Shah ...
... State University are pumping for a controversial theory, which ... into "dark states" where they can be easily dismantled ... some of the most accepted theories in biochemistry. ... by much of the science community, has just in ...
... to reconstruct a complex molecular system of Darwinian evolution for ... genes. ,The research was led by ... Oregon's Center for Ecology and Evolutionary Biology, and will be ... selection can drive the evolution of complex molecular systems – ...
... a study conducted by the University of Erfurt in ... to inflict financial pain to achieve// collective gain. The ... ,Researchers have found that groups in which ... more popular than groups without this option. Though two ...
... at a high risk for developing Alzheimer's disease would benefit ... ibuprofen. This therapy appears to be of maximum benefit in ... is a high-risk condition predisposing them to Alzheimer's disease. ... Baltimore monitored nearly 5000 elderly residents of Cache County in ...
... lymphatic leukemia and dementia, was a regular with a day unit ... mentally decrepit clients. An ambulance team was in charge of picking ... at the residence. ,On August 20th 2003, the ambulance, ... door of an empty house of another patient, after a key ...
Cached Medicine News:Health News:Stress Can Cause Hair loss at 16 2Health News:Controversial Theory Says DNA Can Be Pushed To "Dark States" 2Health News:Controversial Theory Says DNA Can Be Pushed To "Dark States" 3Health News:Scientists Explain Complex Darwinian Evolution 2Health News:Competitive Advantage Are Attained In Which Freeloaders Are Punished 2Health News:Competitive Advantage Are Attained In Which Freeloaders Are Punished 3Health News:Competitive Advantage Are Attained In Which Freeloaders Are Punished 4
... The S7 gives enhanced deliverability ... Platform gives your short-wire capability and ... catheters. Secure Technology Stent Retention ... Discrete Technology designed to minimize balloon ...
The MULTI-LINK RX PENTA Coronary Stent Systems with new ACCESS-LINK Stent Design are indicated for improving coronary luminal diameter....
Now available in 2.75-mm diameters, the S660 small vessel coronary stent expands your treatment options for accurate sizing and precision stenting....
A fusion of first class deliverability, acute angiographic results and excellent versatility....
Medicine Products: